411.65MMarket Cap-3854P/E (TTM)
7.540High7.410Low5.45KVolume7.410Open7.430Pre Close40.53KTurnover0.02%Turnover RatioLossP/E (Static)55.33MShares10.25052wk High-28.73P/B192.56MFloat Cap2.70052wk Low--Dividend TTM25.88MShs Float28.265Historical High--Div YieldTTM1.75%Amplitude2.700Historical Low7.435Avg Price1Lot Size
Foghorn Therapeutics Stock Forum
loading...
loading...
NEWS
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
NEWS
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced plans to host a conference call and webcast on April 9th to review key pipeline programs, including FHD-286 for AML and new preclinical data for FHD-909 and selective CBP and EP300 degrader programs.
No comment yet